title: What's New in HIV/AIDS? Chemokine receptor antagonists: a new era of HIV therapy?
abstract: Chemokine receptors are essential for human immunodeficiency virus (HIV) cell entry. CXCR4 and CCR5 are the two most relevant receptors and by inhibition of each of them a delayed onset of disease could be achieved. As both receptors are used at different stages of disease due to the domination of different HIV strains, a dual blockage of CXCR4 and CCR5 could be highly valuable for inhibiting viral transmission and replication.
authors.affiliation: Department of Infectious Diseases, Medical Policlinic, Ludwig Maximilian University Munich, Pettenkoferstr. 8a, 80336 Munich, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Jülg
authors.forename: F D
authors.initials: FD
authors.lastname: Goebel
mesh_terms: D019380:Anti-HIV Agents / Q000494:pharmacology*; D065100:CCR5 Receptor Antagonists; D002986:Clinical Trials as Topic; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors; D019707:Receptors, Chemokine / Q000037:antagonists & inhibitors*
chemical_list: D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D019718:Receptors, CXCR4; D019707:Receptors, Chemokine